Treace Medical Concepts, Inc (TMCI) News & EventsTMCITreace Medical Concepts, Inc

Treace Medical Reports Q2 Revenue of $45.38M

Reports Q2 revenue $45.38M, consensus $43.92M. "We are pleased with our second quarter results which were driven by accelerating year-over-year case volumes and market share gains resulting from increasing surgeon adoption of our comprehensive bunion portfolio as well as our expanding line of new technologies - now providing us access to a broader range of procedures throughout the foot & ankle," said John T. Treace, CEO and Chairman of Treace Medical. "We continue to focus on investing in growth initiatives to leverage our expanded portfolio, while driving profitability, positioning us for stronger growth in the second half of the year."

Company Raises 2026 Revenue Guidance to $204M-$212M

$221.8M. The company said, "The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million, representing a decline of 4% to 0% compared to full-year 2025. This compares to previous revenue guidance of $202 million to $212 million. The Company is updating its expectation of a loss in Adjusted EBITDA in the range of $3.0 million to $5.0 million for full year 2026, as compared to previous guidance of a loss in the range of $4.0 million to $6.0 million. The Company reported a loss of $3.9 million in the full-year 2025."

Treace Medical Successfully Completes First HyperPlate XM Implant Case

Treace Medical Concepts announced the successful completion of the first case utilizing its HyperPlate XM Dynamic Compression Locking Implant. "The launch of HyperPlate XM implants marks another important step in the continued expansion of our market-leading bunion and midfoot portfolio," said John Treace, CEO and Chairman of Treace. "As we highlighted earlier this year, we remain focused on expanding our procedural reach broadly throughout the foot and ankle. HyperPlate XM implants are an example of that strategy in action, providing surgeons with another innovative solution that complements our existing technologies and supports the growing adoption of our expanding portfolio. We believe HyperPlate XM implants, together with our SuperBite Compression Screws platform, strengthens our ability to participate in a larger addressable market, drive increased procedural utilization, and deepen customer engagement, while further advancing Treace as a comprehensive foot and ankle technology partner."